Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

Hon Yi Lin; Michael W.Y. Chan; Vivian W.Y. Lui; Peter J.K. Kuppen; Shih Kai Hung

doi:10.3389/fonc.2023.1213513

Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

Hon Yi Lin
, Michael W.Y. Chan
, Vivian W.Y. Lui
, Peter J.K. Kuppen
, Shih Kai Hung

The Graduate School

Research output: Contribution to journal › Editorial › peer-review

2 Scopus citations

Original language	English (US)
Article number	1213513
Journal	Frontiers in Oncology
Volume	13
DOIs	https://doi.org/10.3389/fonc.2023.1213513
State	Published - 2023

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

cancer
epigenetic modification
immune-oncology (IO)
immunotherapy
radiotherapy (RT)

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.3389/fonc.2023.1213513

Cite this

@article{86158903c8594a0c95173690106057c3,

title = "Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application",

keywords = "cancer, epigenetic modification, immune-oncology (IO), immunotherapy, radiotherapy (RT)",

author = "Lin, \{Hon Yi\} and Chan, \{Michael W.Y.\} and Lui, \{Vivian W.Y.\} and Kuppen, \{Peter J.K.\} and Hung, \{Shih Kai\}",

note = "Funding Information: The present study was supported by the Ministry of Science and Technology, Taiwan (Grant Number, 106-2923-B-194-001-MY3), and the Buddhist Tzu Chi Medical Foundation (Grant Number, TCMMP105-09-02[-04], TCMMP106-02-02[-04], TCMF-A 111-10, TCMF-A 112-04, and DTCRD106[2]-E-18). ",

year = "2023",

doi = "10.3389/fonc.2023.1213513",

language = "English (US)",

volume = "13",

journal = "Frontiers in Oncology",

issn = "2234-943X",

publisher = "Frontiers Media SA",

}

TY - JOUR

T1 - Editorial

T2 - The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

AU - Lin, Hon Yi

AU - Chan, Michael W.Y.

AU - Lui, Vivian W.Y.

AU - Kuppen, Peter J.K.

AU - Hung, Shih Kai

N1 - Funding Information: The present study was supported by the Ministry of Science and Technology, Taiwan (Grant Number, 106-2923-B-194-001-MY3), and the Buddhist Tzu Chi Medical Foundation (Grant Number, TCMMP105-09-02[-04], TCMMP106-02-02[-04], TCMF-A 111-10, TCMF-A 112-04, and DTCRD106[2]-E-18).

PY - 2023

Y1 - 2023

KW - cancer

KW - epigenetic modification

KW - immune-oncology (IO)

KW - immunotherapy

KW - radiotherapy (RT)

UR - https://www.scopus.com/pages/publications/85161083794

UR - https://www.scopus.com/pages/publications/85161083794#tab=citedBy

U2 - 10.3389/fonc.2023.1213513

DO - 10.3389/fonc.2023.1213513

M3 - Editorial

AN - SCOPUS:85161083794

SN - 2234-943X

VL - 13

JO - Frontiers in Oncology

JF - Frontiers in Oncology

M1 - 1213513

ER -

Editorial: The role of epigenetic modification in radiotherapy and immuno-oncology in cancer: from bench to clinical application

UN SDGs

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this